Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Omeros Corp (GB:0KBU)
LSE:0KBU
Omeros (0KBU) Share Price & Analysis
0 Followers
0KBU Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.99 - $5.68
Previous Close$5.42
Volume1.31K
Average Volume (3M)2.56K
Market Cap
$305.95M
Enterprise Value$347.25M
Total Cash (Recent Filing)$171.85M
Total Debt (Recent Filing)$213.16M
Price to Earnings (P/E)―
Beta3.00
Next Earnings
Aug 07, 2024EPS Estimate
-$0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding57,944,159
10 Day Avg. Volume118
30 Day Avg. Volume2,563
Standard Deviation0.21
R-Squared0.05
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)-9.21
Price to Sales (P/S)767.62
Price to Cash Flow (P/CF)-1.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue231.50
Enterprise Value/Gross Profit231.50
Enterprise Value/Ebitda-3.53
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Omeros News
Bulls Say, Bears Say
Bulls Say
Cash PositionOMER would have total expected cash and investments of approximately $230 million, which should provide a cash runway into 2026.
Debt ManagementThe transactions allow OMER to extend the maturity of 55% of its outstanding debt from 2026 to 2028 without equity dilution.
Regulatory ProgressOMER met with the FDA to request input for Phase 3 studies and BLA submission of OMS906 for treatment of Paroxysmal nocturnal hemoglobinuria, with the FDA confirming the sufficiency of the nonclinical program.
Bears Say
Financial PerformanceThe new loan will accrue interest at a minimum of 11.75% and has a maturity of 2028.
Pipeline DevelopmentHold rating is influenced by the early-stage nature of OMER's pipeline and the lack of near-term value drivers.
Product ApprovalSkepticism remains whether OMER can address the issues highlighted in the 2021 CRL, and put the product candidate on a potential path to FDA approval.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.12% Other Institutional Investors
99.88% Public Companies and
Individual Investors
0KBU FAQ
What was Omeros Corp’s price range in the past 12 months?
Omeros Corp lowest share price was $0.99 and its highest was $5.68 in the past 12 months.
What is Omeros Corp’s market cap?
Currently, no data Available
When is Omeros Corp’s upcoming earnings report date?
Omeros Corp’s upcoming earnings report date is Aug 07, 2024 which is in 11 days.
How were Omeros Corp’s earnings last quarter?
Currently, no data Available
Is Omeros Corp overvalued?
According to Wall Street analysts Omeros Corp’s price is currently Overvalued.
Does Omeros Corp pay dividends?
Omeros Corp does not currently pay dividends.
What is Omeros Corp’s EPS estimate?
Omeros Corp’s EPS estimate is -$0.7.
How many shares outstanding does Omeros Corp have?
Currently, no data Available
What happened to Omeros Corp’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Omeros Corp?
Among the largest hedge funds holding Omeros Corp’s share is Sheaff Brock Investment Advisors LLC. It holds Omeros Corp’s shares valued at 207K.
---
Omeros Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
GB:0KBU Sentiment 100%
Sector Average 72%
Sector Average 72%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.09%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-21.89%
Trailing 12-Months
Company Description
Omeros Corp
Omeros Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.
---
0KBU Earnings Call
Q1 2024
0:00 / 0:00
---
0KBU Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Omeros
―
Alimera
―
ANI Pharmaceuticals
―
Assembly Biosciences
―
Actinium Pharmaceuticals
―
Best Analysts Covering 0KBU
1 Year
1 Year Success Rate
6/8 ratings generated profit
1 Year Average Return
+59.59%
reiterated a buy rating 4 months ago
Copying Stephen Brozak's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +59.59% per trade.
---